AbbVie Inks Sixth Humira Biosimilar Settlement, Battles Boehringer's 'Unclean Hands' Claim
Executive Summary
Boehringer stands out in its decision to litigate rather than settle, and the firm has obtained AbbVie's settlement agreements with other biosimilar makers.
You may also be interested in...
AbbVie's 'Unjustified' Humira Settlements Divide Market, Claims Class Action
First suit challenging biosimilar litigation settlements ratchets up pressure on AbbVie's "patent thicket" and licensing strategy.
AbbVie's 'Unjustified' Humira Settlements Divide Market, Class Action Claims
First suit challenging biosimilar litigation settlements ratchets up pressure on AbbVie's "patent thicket" and licensing strategy.
Biosimilar Vs. Biosimilar: Coherus Sues Amgen For Infringing Adalimumab Formulation Patents
Amgen’s manufacture in California of its biosimilar for the European market infringes three recently issued patents, says Coherus, which is considerably behind Amgen in developing its own copy of AbbVie’s Humira. Lawsuit highlights the key role that intellectual property is likely to play in protecting biosimilar formulations, one patent attorney says.